Global

2016 May Received IND approval for phase III clinical trial for Botualx® in China
Apr Obtained additional indication approval for Botulax® 150Unit (Post-stroke upper-limb spasticity)
Mar Received IND approval for phase III clinical trial for Botulax® in Germany and Poland
2015 Dec Received IND approval for phase III clinical trial for Botulax® in U.S.A
IPO (145020, KOSDAQ)
Jun Entered into partnership with Small Lab Co., Ltd.
Apr Took over HUGEL meditec, Inc.
2014 Dec Received title of 3rd Generation Exemplary Entrepreneur Company from the Presidential Committee on Balanced National Development
Oct Received MFDS approval for “The Chaeum SubQ 20” HA filler
Sep Grand Prize winner in the 3rd Gangwon Employment Ceremony
Jun Selected 2014 Best Companies to Work For
May commercialization of The Chaeum filler
Apr Received MFDS approval for “The Chaeum Volus 20” HA filler
Recognized as an Inno-Biz: small but strong global company
Mar Commendation from the President of the Gangwon Employer’s Federation on Businessmen’s Day
Jan Commendation from the Minister of Trade, Industry & Energy for contribution to the “Hope Project”

Expand

2013 Aug Completed registration for the 2nd Chuncheon factory (cGMP / EUGMP)
Jun Received IND approval for phase III clinical trial for post-stroke spasticity (Protocol)
2012 Nov Obtained additional indication approval for Botulax® (glabellar lines)
Obtained IND approval for “The Chaeum Volus 20” HA filler (Protocol)
Jul Completed construction of cGMP/EUGMP compliant 2nd facility in Chuncheon, G-Tech
Jun Selected 2012 Best Companies to Work For
2011 Dec Received IND approval for phase III clinical trial for pediatric cerebral palsy (Protocol)
Oct Received KFDA approval for Botulax® 50 units
Sep Prime Minister Commendation for “Innovative Botulax” in 2011
Received KFDA approval for Botulax® 200 units
Jul Received IND approval for phase III clinical trial for glabellar lines (Protocol)
Jun Initiation of approval process for international commercialization
2010 Jun Commercialization of Botulax® in the domestic market
Mar Received KFDA approval for Botulax® (blepharospasm)
Feb
Received KFDA approval for Botulax® 200 units export
Received CE 1023, European certification for Hyalsense
Received EN ISO 13485 certification for medical equipment quality control system

Rise

2009 Jun Established ‘HUGEL pharma Co., LTD’, a sales subsidiary
Apr First exports to Japan
Mar Received KFDA approval for Botulax® export
2008 Dec Received approval to manufacture pharmaceuticals
Apr Obtained 3 billion KRW investment in private equity funds through IBK (Industrial Bank of Korea)
2007 Sep Received IND approval for phase III clinical trial for blepharospasm (Protocol)
2006 Oct Installed KGMP system at the 1st factory in Techno Park, Chuncheon
Jul Completed preclinical testing for botulinum toxin type A protein

Beginning

2005 Oct Implemented preclinical testing for botulinum toxin type A protein
Jul Obtained patent for PAAG gel and its indication
2003 Sep Succeeded in purifying botulinum toxin type A protein
Mar Patent application for PAAG manufacturing method
2002 Nov Developed polyacrylamide hydrogel (PAAG)
2001 Nov Established HUGEL, Inc.